Beyond Air (NASDAQ:XAIR – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.
Profitability
This table compares Beyond Air and Cartesian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beyond Air | -632.51% | -261.08% | -119.07% |
| Cartesian Therapeutics | N/A | N/A | -11.95% |
Valuation & Earnings
This table compares Beyond Air and Cartesian Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beyond Air | $5.80 million | 1.13 | -$46.62 million | ($7.58) | -0.11 |
| Cartesian Therapeutics | $38.91 million | 4.52 | -$77.42 million | ($1.56) | -4.34 |
Beyond Air has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Beyond Air and Cartesian Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beyond Air | 1 | 0 | 1 | 1 | 2.67 |
| Cartesian Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Beyond Air currently has a consensus price target of $11.00, suggesting a potential upside of 1,241.46%. Cartesian Therapeutics has a consensus price target of $38.00, suggesting a potential upside of 461.30%. Given Beyond Air’s stronger consensus rating and higher probable upside, research analysts clearly believe Beyond Air is more favorable than Cartesian Therapeutics.
Institutional & Insider Ownership
31.5% of Beyond Air shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 19.4% of Beyond Air shares are held by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Beyond Air has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.
Summary
Cartesian Therapeutics beats Beyond Air on 10 of the 15 factors compared between the two stocks.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
